|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | WSEAS: a bidirectional bluetooth authentication scheme based on game-theoretic framework, al- fred menezes显示文摘 | EL N SYRINE K FOUAD K | 2006 | WSEAS Transactions on Communications2006，15，6： | 1 |
| 2 | Constipation in 44 patients implanted with an artificial bowel sphincter显示文摘 | Syrine Gallas Anne-Marie Leroi Valérie Bridoux Beno?t Lefebure Jean-Jacques Tuech Fran?is Michot | 2009 | International Journal of Colorectal Disease2009，，8： | 1 |
| 3 | Sensory Transcuta neous Electrical Stimulation Improves Post Stroke Dysphagic Pa- tients显示文摘 | Syrine G Jean Paul M Anne Marie L | 2010 | Dysphagia2010，25，4： | 1 |
| 4 | Existence theorem of nonlinear singular boundary value problem显示文摘 | HABIB Maagli SYRINE Masamoudi | 2001 | Nonlinear Anal2001，46，4： | 1 |
| 5 | Sensorytranscutaneous electrical stimulation Improves post-strokedysphagic patients显示文摘 | Syrine Gallas Jean Paul Marie Anne Marie Leroi | 2010 | Dysphagia2010，，4： | 1 |
| 6 | Ghrelin, appetite and gastric electrical stimulation显示文摘 | Syrine Gallas Sergue? O. Fetissov | 2011 | Peptides2011，，11： | 1 |
| 7 | Sensory Transcutaneous Electrical Stimulation Improves Post-Stroke Dysphagic Patients显示文摘 | Syrine Gallas Jean Paul Marie Anne Marie Leroi Eric Verin | 2010 | Dysphagia2010，，4： | 1 |
| 8 | FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study显示文摘BACKGROUND FOLFIRINOX regimen is the first-line reference chemotherapy(L1)in advanced pancreatic ductal adenocarcinoma(aPDAC).FOLFOXIRI,a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil,has demonstrated efficacy and feasibility in colorectal cancer.AIM To investigate the potential clinical value of FOLFOXIRI in patients with aPDAC in routine clinical practice.METHODS Analyses were derived from all consecutive aPDAC patients treated in L1 between January 2011 and December 2017 in two French institutions,with either FOLFOXIRI(n=165)or FOLFIRINOX(n=124)regimens.FOLFOXIRI consisted of irinotecan(165 mg/m2),oxaliplatin(85 mg/m2),leucovorin(200 mg/m2)and 5-fluorouracil(3200 mg/m2 as a 48-h continuous infusion)every 2 wk.Ninety-six pairs of patients were selected through propensity score matching,and clinical outcomes of the two treatment regimens were compared.RESULTS Median overall survival was 11.1 mo in the FOLFOXIRI and 11.6 mo in the FOLFIRINOX cohorts,respectively.After propensity score matching,survival rates remained similar between the two regimens in terms of overall survival(hazard ratio=1.22;P=0.219)and progression-free survival(hazard ratio=1.27;P=0.120).The objective response rate was 37.1%in the FOLFOXIRI group vs 47.8%in the FOLFIRINOX group(P=0.187).Grade 3/4 toxicities occurred in 28.7%of patients in the FOLFOXIRI cohort vs 19.5%in the FOLFIRINOX cohort(P=0.079).FOLFOXIRI was associated with a higher incidence of grade 3/4 digestive adverse events.Hematopoietic growth factors were used after each chemotherapy cycle and the low hematological toxicity rates were below 5%with both regimens.CONCLUSION FOLFOXIRI is feasible in L1 in patients with aPDAC but does not confer any therapeutic benefit as compared with FOLFIRINOX.The low hematological toxicity rates strengthened the relevance of primary prophylaxis with hematopoietic growth factors. | Angélique Vienot Hortense Chevalier Clément Bolognini Elisabeta Gherga Elodie Klajer Aurélia Meurisse Marine Jary Stefano Kim Christelle d’Engremont Thierry Nguyen Fabien Calcagno Hamadi Almotlak Francine Fein Meher Nasri Syrine Abdeljaoued Anthony Turpin Christophe Borg Dewi Vernerey | 2020 | World Journal of Gastrointestinal Oncology2020，12，3： | 0 |
| 9 | CD8^(+)CD226^(high)T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery显示文摘CD226 has been reported to participate in the rescue of CD8^(+)T cell dysfunction.In this study,we aimed to assess the prognostic value of CD226 in tumor-infiltrating lymphocytes(TILs)derived from colorectal cancer(CRC)liver metastases treated with chemotherapy and radical surgery.TILs from 43 metastases were isolated and analyzed ex vivo usingflow cytometry.CD155 and CD3 levels in the tumor microenvironment were assessed by immunohistochemistry.Exploration and validation of biological processes highlighted in this study were performed by bioinformatics analysis of bulk RNA-seq results for 28 CRC liver metastases pretreated with chemotherapy as well as public gene expression datasets.CD226 expression contributes to the definition of the immune context in CRC liver metastases and primary tumors.CD226 on CD8^(+)T cells was not specifically coexpressed with other immune checkpoints,such as PD1,TIGIT,and TIM3,in liver metastases.Multivariate Cox regression analysis revealed CD226 expression on CD8^(+)T cells to be an independent prognostic factor(p=0.003),along with CD3 density at invasion margins(p=0.003)and TIGIT expression on CD4^(+)T cells(p=0.019).CD155 was not associated with the prognostic value of CD226.Gene expression analysis in a validation dataset confirmed the prognostic value of CD226 in CRC liver metastases but not in primary tumors.Downregulation of CD226 on CD8^(+)TILs in the liver microenvironment was restored by IL15 treatment.Overall,CD226 expression on liver metastasis-infiltrating CD8^(+)T cells selectively contributes to immune surveillance of CRC liver metastases and has prognostic value for patients undergoing radical surgery. | Julien Viot Syrine Abdeljaoued Angélique Vienot Evan Seffar Laurie Spehner Adeline Bouard Kamal Asgarov Jean-RenéPallandre Elodie Renaude Elodie Klajer ChloéMolimard Franck Monnien Frederic Bibeau Celia Turco Bruno Heyd Paul Peixoto Eric Hervouet Romain Loyon Alexandre Doussot Christophe Borg Marie Kroemer | 2023 | Cellular & Molecular Immunology2023，20，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员